Figure 1.
Subject accounting in base study and extension.
804 EVG subjects and 703 CVG subjects took part in the Colombian extension study. Data were available for 684 subjects in the EVG and 651 CVG subjects.
Table 1.
Baseline characteristics of subjects in Colombia at the time of vaccination dose 1 in the base study.
Table 2.
Effectiveness of qHPV vaccination in women 24–45 years of age against HPV 6/11/16/18-related CIN or condyloma (cumulative incidence in the EVG, day 1 to year 6).
Table 3.
Effectiveness of qHPV vaccination in women 24 to 45 years of age against HPV 31/33/35/39/45/51/52/56/58/59-related CIN or condyloma (cumulative incidence, day 1 to year 6 in the EVG FAS population).
Table 4.
Comparison of 2-year incidence rates of vaccine and non-vaccine HPV type-related endpoints.
Table 5.
Summary of month 72 HPV seropositivity rates by age (per-protocol immunogenicity population participating in follow-up).